Philogen (PHIL) H2 2025 earnings summary

Executive summary

• Full-year 2025 results highlighted scientific and financial progress, with a robust pipeline in antibody and small molecule therapeutics targeting oncology and other diseases.

• Total revenue reached €320.1 million for FY2025, up €242.5 million year-over-year, driven by a €300 million upfront payment from a licensing deal with RayzeBio (BMS Group) for OncoACP3 targeting prostate cancer.

• Expansion of clinical activities at the Milano site, with increased emphasis on data science and clinical science.

• Strategy centers on delivering proven therapeutic payloads to tumors using proprietary ligands for enhanced selectivity and efficacy.

• Pipeline has grown significantly since 2021, with multiple new trials launched and several programs advancing to late-stage clinical development.

Financial highlights

• Achieved net profit of €229.7 million for 2025, up from €45.3 million in 2024.

• Cash and cash equivalents at year-end 2025 were €379.2 million, with a positive net financial position of €368.3 million, up 260% year-over-year.

• Revenue from contracts with customers rose 325% year-over-year to €314.3 million, mainly due to the RayzeBio licensing agreement.

• Decision to issue a dividend of €0.70 per share based on strong financial performance, subject to shareholder approval.

• Monthly spending in 2025 was around €4 million, with expectations to remain stable or slightly increase in 2026.

Outlook and guidance

• Nidlegy marketing authorization application on track for July 2026 submission in Europe, with a decision expected by mid-2027.

• Ongoing and planned clinical trials for key pipeline assets, including new registrational studies for Nidlegy in skin cancers and Fibromun in soft tissue sarcoma.

• Expansion of clinical pipeline with new studies in BCC, CSCC, and glioblastoma, and further development of small molecule platforms.

• Continued focus on first-line soft tissue sarcoma and first-line glioblastoma as key growth areas.

• Ongoing investment in discovery and data science to support future pipeline expansion.